Multi-Modal Anesthesia Protocol in Pain Management of Patients Undergoing Posterior Lumbar Spinal Fusion Surgery
Summary
This study consisted of a randomized controlled trial designed to evaluate a Multimodal Analgesia (MMA) Protocol on patients undergoing Posterior Spinal Fusion. The purpose is to describe the narcotic requirements and usage during the perioperative period of posterior spinal fusion and instrumentation surgery with the implementation of multimodal anesthesia protocol. The study will consist of two parallel arms, with Group 1 receiving our MMA protocol and Group 2 receiving a traditional opioid-based regime. The primary outcome of this study will be the reported Visual Analog Scale (VAS) for pain at 12, 24, and 48 hours after surgery. We considered that our findings could contribute to the fight against the opioid crisis proving alternatives to opioids as feasible alternatives for pain management even in significant surgery, as is posterior spinal fusion with instrumentation.
Timeline
- Start
- 2021-04-05
- Primary completion
- 2022-01-28
- Completion
- 2022-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acetaminophen | Small molecule | 1000 mg | Oral |
| Subject | Bupivacaine | Other / unclassified | 30 ml | Other |
| Subject | Epinephrine | Other / unclassified | 1 ml | Other |
| Subject | Gabapentin | Small molecule | 300 mg | Oral |
| Subject | Ketorolac Tromethamine | Small molecule | 30 mg | Intravenous |
| Subject | Methylprednisolone | Other / unclassified | 125 mg | — |
| Comparator | Morphine | Other / unclassified | 4 mg | Intravenous |
| Subject | Orphenadrine | Small molecule | 100 mg | Oral |
| Subject | Xylocaine Injectable Solution | Unknown | 0.5 % | Intramuscular |
Indications
No indication recorded.